Always xpect d unxpect
I expected ccs after each of the last e earnings releases
I expected a and z and a p3 blessed by the fda after the gog 186i data
If u said that i stand corrected.I did look up your last month or so of posts and did not see it.How did you vote on rs and options?All of us with so called agendas think the drug works.Posting drug sale estimates maybe good for shareholders in 18 months or 2 years but not when we are looking down the barrel of a 3rd rs and exec options next year off the charts and a 66c pps.I did put u on our mb bod for a reason
Great post sandman.
If mel asks all those questions , he may get only get 1 question answered if that.
Cliff u r so wrong.our agenda is for a sale of the company now.And if u need to ask why then u have had blinders on for 26 months if not longer
Maybe you r paid or tied into management.do ya think?
You seem oblivious to mgmt and the pps.jpn said it all.
What about focus being done cause chemo and avast r soc.So focus still uses poison in both arms.
Gog 186i WAS WITHOUT CHEMO.But p3 from it was shelved.
So whats the non toxic alternative if chemo is in both arms.
Is it a dumb question ?you are our science dude
multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase 2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo in subjects with platinum-resistant ovarian cancers (prOC). Subjects with platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or fallopian tube cancer will be randomized 1:1 to receive PCC plus bevacizumab and CA4P or PCC plus bevacizumab and placebo. Subjects will be stratified by selected chemotherapy (PLD vs. paclitaxel), platinum free interval (
Jake.i know .that was brought to our attention i think when scweity dropped the bombshell on us and we lost like 30 or 40c immediately that not pursuing p3 off 186i but instead doing 2 p2p3 s triple combo.
Who knows vass.
To me this is unchartered territory.my guess is it gets voted down or like mano said they postpone something if they can.I say it cause of how we voted plus mgmt putting out the letter and last yr shareholders saying no to auth share increase prop.
Yes cliff.the 40 will be rolled into 60 and then 80.
The pfs (endpoint) should be good.I have never been short.I probably own half the number of shares as jake and what i or you post i doubt has had now or ever had any bearing on the pps of oxgn..I will not say z will b a billion dollar drug.How would i know.I am a longtime shareholder in and out but in since march 2014 with varying number of shares..i just think that the dollar sales of z is irrelevant now cause its years away and now the next 10 to 12 mos is what matter.And for this moment maybe the next 2 mos matter.Whats your thought on timing of stat sig os
Yes cliff but they 86ed the p3 which fda cleared and lost possibly 1 or 2 years by doing a triple combo with chemo in a new p2.